Bavarian Nordic – Ineffective Cancer Vaccine Masked By Misleading Data: Kerrisdale

Is Bavarian Nordic Dendreon 2.0? Ineffective Cancer Vaccine Masked By Misleading Data by Sahm Adrangi, Kerrisdale Capital

Bavarian Nordic is a $1.3B Danish vaccine-maker whose stock price has recently surged (up 63% YTD) thanks to excitement over its putative prostate cancer treatment, Prostvac-VF, a therapeutic vaccine currently undergoing a Phase III clinical trial. Bavarian Nordic touts its earlier Phase II study of Prostvac as showing  the “most pronounced survival to date in...

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

Bavarian Nordic [+]    Sahm Adrangi [+]    Kerrisdale Capital [+]    Danish [+]    YTD [+]    Prostvac [+]    Phase III [+]    Phase II [+]   

More #news: